Valink Therapeutics Secures $11.8 Million Pre‑A to Advance Next-Generation Bispecific ADC Oncology Pipeline
Valink Therapeutics, the Cambridge, Massachusetts and London‑linked biotechnology company developing next‑generation oncology therapeutics, has closed an $11.8 million Pre‑A financing round to accelerate development of its…
